Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

被引：0

作者：

Sasaki, Koji ^{[1
]}

Rodriguez-Rivera, Ildefonso Ismael ^{[2
]}

Kantarjian, Hagop M. ^{[1
]}

O'Brien, Susan ^{[1
]}

Jabbour, Elias ^{[1
]}

Borthakur, Gautam ^{[1
]}

Ravandi, Farhad ^{[1
]}

Burke, Michael J. ^{[3
]}

Zweidler-McKay, Patrick A. ^{[1
]}

Cortes, Jorge E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Texas Southwestern, Austin, TX USA

[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] CORRELATION OF DASATINIB PHARMACOKINETICS WITH CLINICAL RESPONSE AND ADVERSE EVENTS IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA CHRONIC PHASE
Mita, A.
Miura, M.
Niioka, T.
Abumiya, M.
Kobayasi, T.
Takahshi, S.
Kameoka, Y.
Yoshioka, T.
Takahashi, N.
HAEMATOLOGICA, 2015, 100 : 694 - 694
[22] Severe Adverse Events By First Line Tyrosine Kinase Inhibitors Decrease Survival Rate in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Ota, Shuichi
Matsukawa, Toshihiro
Yamamoto, Satoshi
Ito, Shinichi
Shindo, Motohiro
Sato, Kazuya
Kondo, Takeshi
Takahashi, Tohru
Sato, Tsutomu
Kakinoki, Yasutaka
Kobayashi, Hajime
Kurosawa, Mitsutoshi
BLOOD, 2016, 128 (22)
[23] Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase
Hu, Bei
Savani, Bipin N.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (03) : 179 - 186
[24] Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 223 - 224
[25] New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia
le Coutre, Philipp
Schwarz, Michaela
Kim, Theo D.
CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1771 - 1780
[26] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Pierre Laneuville
Current Treatment Options in Oncology, 2018, 19
[27] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Laneuville, Pierre
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (03)
[28] ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA
Yadrikhinskaya, V. N.
Mulina, I. I.
Sannikova, A. N.
Palshina, A. M.
Sleptsova, S. S.
Aleksandrova, T. N.
YAKUT MEDICAL JOURNAL, 2016, (04): : 30 - 33
[29] Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Baccarani, Michele
Castagnetti, Fausto
Gugliotta, Gabriele
Palandri, Francesca
Rosti, Gianantonio
EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (03) : 397 - 406
[30] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Giles, F. J.
O'Dwyer, M.
Swords, R.
LEUKEMIA, 2009, 23 (10) : 1698 - 1707

← 1 2 3 4 5 →